{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T19:24:05Z","timestamp":1792265045331,"version":"4.4.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.lungcan.2025.108813","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T16:17:03Z","timestamp":1762186623000},"page":"108813","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["First-line immunotherapy\u00a0\u00b1\u00a0chemotherapy with or without upfront stereotactic radiotherapy (SRT) in patients with Non-Small cell lung cancer (NSCLC) with asymptomatic brain metastases"],"prefix":"10.1016","volume":"210","author":[{"given":"Lorenz","family":"Frehner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e4mi","family":"Sch\u00e4r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Hayoz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Verena","family":"Petermichl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Speicher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1304-9340","authenticated-orcid":false,"given":"Sacha","family":"I. Rothschild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6652-1947","authenticated-orcid":false,"given":"Laetitia A.","family":"Mauti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"K\u00f6nig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Finazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Froesch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Marini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Allemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Mark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolf-Dieter","family":"Janthur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Stamatiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yannis","family":"Metaxas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekin","family":"Ermi\u015f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franca","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Fr\u00fch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.lungcan.2025.108813_b0005","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41572-018-0055-y","article-title":"Brain metastases","volume":"5","author":"Achrol","year":"2019","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.lungcan.2025.108813_b0010","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ctrv.2018.05.015","article-title":"Non-small cell lung cancer brain metastases and the immune system: from brain metastases development to treatment","volume":"68","author":"El Rassy","year":"2018","journal-title":"Cancer Treat. Rev."},{"issue":"1","key":"10.1016\/j.lungcan.2025.108813_b0015","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1093\/neuonc\/nou099","article-title":"Incidence of brain metastasis at initial presentation of lung cancer","volume":"17","author":"Villano","year":"2015","journal-title":"Neuro Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2025.108813_b0020","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1136\/jcp.2003.013623","article-title":"Pathobiology of brain metastases","volume":"58","author":"Nathoo","year":"2005","journal-title":"J. Clin. Pathol."},{"issue":"1","key":"10.1016\/j.lungcan.2025.108813_b0025","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.lungcan.2015.01.020","article-title":"Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers","volume":"88","author":"Rangachari","year":"2015","journal-title":"Lung Cancer"},{"issue":"11","key":"10.1016\/j.lungcan.2025.108813_b0030","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1016\/j.jtho.2021.06.019","article-title":"Updated overall survival analysis from IMpower110: atezolizumab versus platinum-based chemotherapy in treatment-naive programmed death-ligand 1-selected NSCLC","volume":"16","author":"Jassem","year":"2021","journal-title":"J. Thorac. Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2025.108813_b0035","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1200\/JCO.2011.38.0527","article-title":"Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases","volume":"30","author":"Sperduto","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.lungcan.2025.108813_b0040","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41571-025-01013-1","article-title":"Stereotactic radiosurgery for patients with brain metastases: current principles, expanding indications and opportunities for multidisciplinary care","volume":"22","author":"Mansouri","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2025.108813_b0045","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/S0360-3016(00)80024-3","article-title":"Randomized treatment of brain metastasis with gamma knife radiosurgery, whole brain radiotherapy or both","volume":"48","author":"Chougule","year":"2000","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.lungcan.2025.108813_b0050","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/1748-717X-9-116","article-title":"Management of brain metastases with stereotactic radiosurgery alone versus whole brain irradiation alone versus both","volume":"9","author":"El Gantery","year":"2014","journal-title":"Radiat Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2025.108813_b0055","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1001\/jamaoncol.2015.1145","article-title":"Japanese radiation oncology study group 99-1 (JROSG 99-1) investigators. Stereotactic radiosurgery with or without whole-brain radiotherapy for brain metastases: secondary analysis of the JROSG 99-1 randomized clinical trial","volume":"1","author":"Aoyama","year":"2015","journal-title":"JAMA Oncol."},{"issue":"5","key":"10.1016\/j.lungcan.2025.108813_b0060","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.ijrobp.2017.07.045","article-title":"Stereotactic radiosurgery with or without whole-brain radiation therapy for limited brain metastases: a secondary analysis of the north central cancer treatment group N0574 (Alliance) randomized controlled trial","volume":"99","author":"Churilla","year":"2017","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"2","key":"10.1016\/j.lungcan.2025.108813_b0065","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1093\/neuonc\/now241","article-title":"Diagnosis and treatment of brain metastases from solid tumors: guidelines from the european association of neuro-oncology (EANO)","volume":"19","author":"Soffietti","year":"2017","journal-title":"Neuro Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2025.108813_b0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10143-007-0110-8","article-title":"Radiosurgery in the treatment of brain metastases: critical review regarding complications","volume":"31","author":"Maldaun","year":"2008","journal-title":"Neurosurg. Rev."},{"issue":"5","key":"10.1016\/j.lungcan.2025.108813_b0075","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1200\/JCO.21.02314","article-title":"Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline [published correction appears in J Clin Oncol. 2022; 40(12):1392. doi: 10.1200\/JCO.22.00593.]","volume":"40","author":"Vogelbaum","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.lungcan.2025.108813_b0080","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1093\/neuonc\/not085","article-title":"Bevacizumab as a treatment for radiation necrosis of brain metastases post stereotactic radiosurgery","volume":"15","author":"Boothe","year":"2013","journal-title":"Neuro Oncol."},{"issue":"21","key":"10.1016\/j.lungcan.2025.108813_b0085","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1200\/JCO.21.00174","article-title":"Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score \u2265 50","volume":"39","author":"Reck","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.lungcan.2025.108813_b0090","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/S1470-2045(23)00329-7","volume":"24","author":"\u00d6zg\u00fcro\u011flu","year":"2023","journal-title":"Lancet Oncol."},{"issue":"11","key":"10.1016\/j.lungcan.2025.108813_b0095","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1200\/JCO.22.01989","article-title":"Pembrolizumab plus pemetrexed and platinum in nonsquamous non-small-cell lung cancer: 5-year outcomes from the phase 3 KEYNOTE-189 study","volume":"41","author":"Garassino","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.lungcan.2025.108813_b0100","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1200\/JCO.22.01990","article-title":"Pembrolizumab plus chemotherapy in squamous non-small-cell lung cancer: 5-year update of the phase III KEYNOTE-407 study","volume":"41","author":"Novello","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.lungcan.2025.108813_b0105","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/j.jtho.2021.07.009","article-title":"IMpower150 final overall survival analyses for atezolizumab plus bevacizumab and chemotherapy in first-line metastatic nonsquamous NSCLC","volume":"16","author":"Socinski","year":"2021","journal-title":"J. Thorac. Oncol."},{"issue":"7","key":"10.1016\/j.lungcan.2025.108813_b0110","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S1470-2045(19)30167-6","article-title":"Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"West","year":"2019","journal-title":"Lancet Oncol."},{"issue":"6","key":"10.1016\/j.lungcan.2025.108813_b0115","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.jtho.2023.03.008","article-title":"Cemiplimab plus chemotherapy versus chemotherapy alone in advanced NSCLC: 2-year follow-up from the phase 3 EMPOWER-lung 3 Part 2 Trial [published correction appears in J Thorac Oncol. 2025 Jan;20(1):119-121. doi: 10.1016\/j.jtho.2023.07.011]","volume":"18","author":"Makharadze","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2025.108813_b0120","article-title":"First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update [published correction appears","author":"Reck","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.lungcan.2025.108813_b0125","unstructured":"Brahmer JR, Lee JS, Ciuleanu TE, et al. Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung."},{"issue":"6","key":"10.1016\/j.lungcan.2025.108813_b0130","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1200\/JCO.22.00975","article-title":"Durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for metastatic non-small-cell lung cancer: the phase III POSEIDON study","volume":"41","author":"Johnson","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.lungcan.2025.108813_b0135","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1016\/j.jtho.2021.06.020","article-title":"Outcomes with Pembrolizumab plus platinum-based chemotherapy for patients with NSCLC and stable brain metastases: pooled analysis of KEYNOTE-021, -189, and -407","volume":"16","author":"Powell","year":"2021","journal-title":"J. Thorac. Oncol."},{"issue":"8","key":"10.1016\/j.lungcan.2025.108813_b0140","article-title":"Outcomes with pembrolizumab monotherapy in patients with programmed death-ligand 1-positive NSCLC with brain metastases: pooled analysis of KEYNOTE-001, 010, 024, and 042","volume":"2","author":"Mansfield","year":"2021","journal-title":"JTO Clin. Res. Rep."},{"issue":"23","key":"10.1016\/j.lungcan.2025.108813_b0145","first-page":"00525","article-title":"Systemic and intracranial outcomes with first-line nivolumab plus ipilimumab in patients with metastatic non-small cell lung cancer and baseline brain metastases from CheckMate 227 Part 1 [published online ahead of print, 2023 May 3]","author":"Reck","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2025.108813_b0150","doi-asserted-by":"crossref","unstructured":"Paz-Ares LG, Ciuleanu TE, Cobo M, et al. First-line nivolumab plus ipilimumab with chemotherapy versus chemotherapy alone for metastatic NSCLC in CheckMate 9LA: 3-year clinical update and outcomes in patients with brain metastases or select somatic mutations, J. Thoracic Oncol., 18 (2), 204\u2013222.","DOI":"10.1016\/j.jtho.2022.10.014"},{"issue":"2","key":"10.1016\/j.lungcan.2025.108813_b0155","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006127","article-title":"First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817","volume":"11","author":"Ready","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.lungcan.2025.108813_b0160","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.22.02561","article-title":"Phase II trial of atezolizumab combined with carboplatin and pemetrexed for patients with advanced nonsquamous non-small-cell lung cancer with untreated brain metastases (Atezo-Brain, GECP17\/05)","author":"Nadal","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.lungcan.2025.108813_b0165","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1470-2045(16)30053-5","article-title":"Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial","volume":"17","author":"Goldberg","year":"2016","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2025.108813_b0170","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S1470-2045(24)00643-0","article-title":"Brain radiotherapy combined with camrelizumab and platinum-doublet chemotherapy for previously untreated advanced non-small-cell lung cancer with brain metastases (C-Brain): a multicentre, single-arm, phase 2 trial","volume":"26","author":"Xu","year":"2025","journal-title":"Lancet Oncol."},{"issue":"14","key":"10.1016\/j.lungcan.2025.108813_b0175","doi-asserted-by":"crossref","first-page":"4202","DOI":"10.1158\/1078-0432.CCR-18-1627","article-title":"Brain Tumor Microenvironment and Host State: Implications for Immunotherapy","volume":"25","author":"Tomaszewski","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.lungcan.2025.108813_b0180","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1093\/annonc\/mdz207","article-title":"Suppressed immune microenvironment and repertoire in brain metastases from patients with resected non-small-cell lung cancer","volume":"30","author":"Kudo","year":"2019","journal-title":"Ann. Oncol."},{"issue":"10","key":"10.1016\/j.lungcan.2025.108813_b0185","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002684","article-title":"Spatially resolved analysis of the T cell immune contexture in lung cancer-associated brain metastases","volume":"9","author":"Lu","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.lungcan.2025.108813_b0190","article-title":"Genomic and Immune Landscape of Non-Small Cell Lung Cancer Brain Metastases","volume":"9","author":"Liu","year":"2025","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.lungcan.2025.108813_b0195","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.lungcan.2018.12.017","article-title":"Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: Exploratory analyses of the phase III OAK study","volume":"128","author":"Gadgeel","year":"2019","journal-title":"Lung Cancer"},{"issue":"5","key":"10.1016\/j.lungcan.2025.108813_b0200","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S1470-2045(20)30111-X","article-title":"Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial","volume":"21","author":"Goldberg","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2025.108813_b0205","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1200\/JCO.2025.43.16_suppl.2011","article-title":"Stereotactic radiation versus hippocampal avoidance whole brain radiation in patients with 5-20 brain metastases: a multicenter, phase 3 randomized trial","volume":"43","author":"Aizer","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2025.108813_b0210","article-title":"Immunotherapy with radiotherapy for brain metastases in patients with NSCLC: NEJ060","volume":"5","author":"Tozuka","year":"2024","journal-title":"JTO Clin Res Rep."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500225007056?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500225007056?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T21:53:29Z","timestamp":1764798809000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500225007056"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":42,"alternative-id":["S0169500225007056"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2025.108813","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"First-line immunotherapy\u00a0\u00b1\u00a0chemotherapy with or without upfront stereotactic radiotherapy (SRT) in patients with Non-Small cell lung cancer (NSCLC) with asymptomatic brain metastases","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2025.108813","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"108813"}}